Monthly Oral Ibandronate Stacks Up In Japan Trial
This article was originally published in PharmAsia News
Executive Summary
Chugai and partner Taisho have released new data from a Phase III Japanese trial with a once-monthly oral formulation of ibandronate for osteoporosis that has confirmed non-inferiority to the injected product and forms the basis of a recent approval filing.